Abiopharma

🔍 SR ONE CAPITAL MANAGEMENT, LLC (Executive)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 474,048 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 474,048.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 139,366 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 613,414.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 59,692 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 673,106.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Acquired 61,762 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 734,868.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Acquired 683,817 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 1,418,685.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Acquired 191,541 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | shares_owned_after: 1,610,226.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 1,065 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 1,609,161.00 | transaction_form_type: 4 | Footnotes: F7, F8, F2
• Acquired 222,222 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: false | shares_owned_after: 1,831,383.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 118,512 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 118,512.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Acquired 255,823 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 374,335.00 | transaction_form_type: 4 | Footnotes: F4, F9
• Acquired 204,658 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 204,658.00 | transaction_form_type: 4 | Footnotes: F4, F10
• Acquired 20,582 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 225,240.00 | transaction_form_type: 4 | Footnotes: F5, F10
• Acquired 166,168 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 391,408.00 | transaction_form_type: 4 | Footnotes: F6, F10
• Acquired 49,850 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | shares_owned_after: 441,258.00 | transaction_form_type: 4 | Footnotes: F7, F10
• Sold 277 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 440,981.00 | transaction_form_type: 4 | Footnotes: F7, F11, F10
• Acquired 133,333 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: false | shares_owned_after: 574,314.00 | transaction_form_type: 4 | Footnotes: F10
• Acquired 463,106 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 463,106.00 | transaction_form_type: 4 | Footnotes: F5, F12
• Acquired 273,527 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 736,633.00 | transaction_form_type: 4 | Footnotes: F6, F12
• Acquired 78,656 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | shares_owned_after: 815,289.00 | transaction_form_type: 4 | Footnotes: F7, F12
• Sold 438 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 814,851.00 | transaction_form_type: 4 | Footnotes: F7, F13, F12
• Acquired 200,000 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: false | shares_owned_after: 1,014,851.00 | transaction_form_type: 4 | Footnotes: F12
• Sold 474,048 shares of Series A Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 139,366 shares of Series A-2 Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F2
• Sold 59,692 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F2
• Sold 61,762 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F5, F5, F5, F2
• Sold 683,817 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F6, F6, F6, F6, F2
• Sold 191,541 shares of Series D Warrants (Right to Buy) at $0.1 per share (Derivative)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F7, F7, F7, F2
• Sold 118,512 shares of Series A Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F9
• Sold 255,823 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F9
• Sold 204,658 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F10
• Sold 20,582 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F5, F5, F5, F10
• Sold 166,168 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F6, F6, F6, F6, F10
• Sold 49,850 shares of Series D Warrants (Right to Buy) at $0.1 per share (Derivative)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F7, F7, F7, F10
• Sold 463,106 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F5, F5, F5, F12
• Sold 273,527 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F6, F6, F6, F6, F12
• Sold 78,656 shares of Series D Warrants (Right to Buy) at $0.1 per share (Derivative)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F7, F7, F12

Footnotes:

• F1: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F2: The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Capital Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
• F3: The Series A-2 Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.3268 basis for no additional consideration.
• F4: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
• F5: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F6: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F7: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
• F8: Pursuant to the terms of the warrants, the Issuer withheld 1,065 warrant shares to pay the exercise price in connection with the net exercise.
• F9: The securities are directly held by SR One Co-Invest IV, LLC ("SR One Co-Invest IV"). SR One Co-Invest IV Manager, LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest IV, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
• F10: The securities are directly held by SR One Co-Invest IV-A, LLC ("SR One Co-Invest IV-A"). SR One Co-Invest IV Manager is the managing member of SR One-Co-Invest IV-A, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
• F11: Pursuant to the terms of the warrants, the Issuer withheld 277 warrant shares to pay the exercise price in connection with the net exercise.
• F12: The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
• F13: Pursuant to the terms of the warrants, the Issuer withheld 438 warrant shares to pay the exercise price in connection with the net exercise.